Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2018
SKU ID :DEL-11471712 | Published Date: 01-Jan-2018 | No. of pages: 84Description
TOC
1. Report Introduction
2. Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2018 Overview
3. Pipeline Therapeutics
• An Overview of Pipeline Products for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2018
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
7. Therapeutic Assessment
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Tables & Figures
Table 1: Total Products for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2018
Table 2: Products in Clinical Stage
Table 3: Products in Non-clinical Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products
Figure 1: Total Products for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2018
Figure 2: Products in Clinical Stage
Figure 3: Products in Non-clinical Stage
Figure 4: Assessment by Route of Administration
Figure 5: Assessment by Stage and Route of Administration
Figure 6: Assessment by Molecule Type
Figure 7: Assessment by Stage and Molecule Type
Figure 8: Inactive Products
Companies
Ionis Pharmaceutical
H3 Biomedicine Inc
Daiichi Sankyo Inc.
Blueprint Medicines Corp.
Incyte Corporation
Genosco
AstraZeneca
Eli Lilly
& list continues...
- PRICE
-
$1250$4000